Melola Discovery

← Melola Discovery

Jurnal SINTA 1

In-hospital Mortality Reduction among Heart Failure Patients Treated with Optimal Dose of Angiotensin-Converting Enzyme Inhibitors

Heart Science Journal · Vol. 1 No. 1 (2020) · hlm. 8–14

DOI
10.21776/ub.hsj.2020.001.01.3
ISSN
2721-9984, 2721-9976
Terbit
2020-04-01
Penerbit
Universitas Brawijaya
Bahasa
en

Abstrak

Background: Angiotensin-converting enzyme inhibitors (ACEI) should be titrated to the optimal dose for adequate inhibition of the Renin-Angiotensin-Aldosterone system (RAAS). The up-titration of ACEI to the optimal doses during in-hospital treatment is challenging.Objectives: This study aimed to investigate whether the use of optimal dose of ACEI during in-hospital treatment could give more benefit to the outcome of heart failure (HF) patients.Methods: We involved 171 HF patients in this prospective cohort study. 29 and 142 HF patients were treated with optimal dose and suboptimal dose of ACEI during in-hospital treatment, respectively. The primary endpoint was in-hospital and 30 days post-discharge mortality. The secondary endpoint was 30 days post-discharge rehospitalization due to worsening of HF.Results: Only 17% of HF patients treated with optimal dose of ACEI during in-hospital treatment. In-hospital mortality in optimal dose of ACEI group was lower than in suboptimal dose of ACEI group (0% vs. 19.7%; p = 0.009). The 30 days post-discharge mortality (0% vs 2.7%; p = 0.375) and rehospitalization (6.9% vs 16.7%; p = 0.184) between both groups were not significantly different.Conclusion: The use of optimal dose of ACEI during in-hospital treatment reduced in-hospital mortality in HF patients.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 306 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • University of Brawijaya
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Cholid Tri TjahjonoUniversity of Brawijaya55
Indra PrasetyaUniversity of Brawijaya49
Ardian RizalUniversity of Brawijaya46
Anna Fuji RahimahUniversity of Brawijaya44
Novi KurnianingsihUniversity of Brawijaya44
Heny MartiniUniversity of Brawijaya18
Muhammad Rizki FadlanUniversity of Brawijaya12
Putri Annisa KamilaUniversity of Brawijaya10
Adhika Prastya WikanandaUniversity of Brawijaya8
Dadang HendrawanUniversity of Brawijaya8
Valerinna Yogibuana Swastika PutriUniversity of Brawijaya8
Wella KarolinaUniversity of Brawijaya7
Anna Fuji RahimahAfiliasi tidak diketahui7
Tri AstiawatiUniversity of Brawijaya6
Valerinna YogibuanaAfiliasi tidak diketahui6
Ayu Asri Devi AdityawatiUniversity of Brawijaya6
Shalahuddin Suryo BaskoroUniversity of Brawijaya6
Hayla Iqda MillisaniUniversity of Brawijaya5
Dea Arie KurniawanUniversity of Brawijaya5
Imelda KrisnasariUniversity of Brawijaya5
Teguh AryanugrahaUniversity of Brawijaya5
Imam Mi'raj SuprayogaUniversity of Brawijaya5
Oktivani Adelathifa RahmaUniversity of Brawijaya4
Krishna Ari NugrahaUniversity of Brawijaya4
Seprian WidasmaraUniversity of Brawijaya4
Evit RuspionoAfiliasi tidak diketahui4
Lutfi Hafiz ZunardiUniversity of Brawijaya4
Nikhen NoverikeUniversity of Brawijaya4
Fandy HazzyUniversity of Brawijaya3
Ratna PancasariUniversity of Brawijaya3
Yuri AfifahUniversity of Brawijaya3
Ira Vori NugrohoUniversity of Brawijaya3
Zhafran VeliawanUniversity of Brawijaya3

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://heartscience.ub.ac.id/index.php/heartscience/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">In-hospital Mortality Reduction among Heart Failure Patients Treated with Optimal Dose of Angiotensin-Converting Enzyme Inhibitors</dc:title>
	<dc:creator xml:lang="en">Utomo, Yoseph Budi</dc:creator>
	<dc:creator xml:lang="en">Rohman, Mohammad Saifur</dc:creator>
	<dc:creator xml:lang="en">Waranugraha, Yoga</dc:creator>
	<dc:creator xml:lang="en">Sargowo, Djanggan</dc:creator>
	<dc:creator xml:lang="en">Widito, Sasmojo</dc:creator>
	<dc:creator xml:lang="en">Satrijo, Budi</dc:creator>
	<dc:creator xml:lang="en">Anjarwani, Setyasih</dc:creator>
	<dc:subject xml:lang="en">Angiotensin-converting enzyme inhibitor</dc:subject>
	<dc:subject xml:lang="en">Heart failure</dc:subject>
	<dc:subject xml:lang="en">Optimal dose</dc:subject>
	<dc:description xml:lang="en">Background : Angiotensin-converting enzyme inhibitors (ACEI) should be titrated to the optimal dose for adequate inhibition of the Renin-Angiotensin-Aldosterone system (RAAS). The up-titration of ACEI to the optimal doses during in-hospital treatment is challenging.Objectives : This study aimed to investigate whether the use of optimal dose of ACEI during in-hospital treatment could give more benefit to the outcome of heart failure (HF) patients.Methods : We involved 171 HF patients in this prospective cohort study. 29 and 142 HF patients were treated with optimal dose and suboptimal dose of ACEI during in-hospital treatment, respectively. The primary endpoint was in-hospital and 30 days post-discharge mortality. The secondary endpoint was 30 days post-discharge rehospitalization due to worsening of HF.Results: Only 17% of HF patients treated with optimal dose of ACEI during in-hospital treatment. In-hospital mortality in optimal dose of ACEI group was lower than in suboptimal dose of ACEI group (0% vs. 19.7%; p = 0.009). The 30 days post-discharge mortality (0% vs 2.7%; p = 0.375) and rehospitalization (6.9% vs 16.7%; p = 0.184) between both groups were not significantly different.Conclusion: The use of optimal dose of ACEI during in-hospital treatment reduced in-hospital mortality in HF patients.</dc:description>
	<dc:publisher xml:lang="en">Universitas Brawijaya</dc:publisher>
	<dc:date>2020-04-01</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://heartscience.ub.ac.id/index.php/heartscience/article/view/23</dc:identifier>
	<dc:identifier>10.21776/ub.hsj.2020.001.01.3</dc:identifier>
	<dc:source xml:lang="en">Heart Science Journal; Vol. 1 No. 1 (2020): The Importance of Adherence to The Guidelines; 8-14</dc:source>
	<dc:source>2721-9984</dc:source>
	<dc:source>2721-9976</dc:source>
	<dc:source>10.21776/ub.hsj.2020.001.01</dc:source>
	<dc:language>en</dc:language>
	<dc:relation>https://heartscience.ub.ac.id/index.php/heartscience/article/view/23/332</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2020 Heart Science Journal</dc:rights>
</oai_dc:dc>